Teva

CINQAIR

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Teva

Cinqair HCPCS:

J2786

HCPCS Code Descriptor:

Injection, reslizumab, 1 mg

Category:

J Code

Cinqair NDCs:

59310-0610-31

Primary Type:

Anti-Eosinophil Asthma

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Cinqair CPT Codes:

Potential CPT administration codes for Cinqair can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Cinqair:

CINQAIR is an Anti-Eosinophil Asthma drug manufactured by Teva and administered via the Intravenous route of administration. The J Code: J2786 is aligned to the drug CINQAIR.

ACCESS PRICING AND MORE BY REGISTERING

J2786 Added Date:

January 1, 2017

J2786 Effective Date:

January 1, 2017

J2786 Termination Date:

HCPCS Active

Cinqair billing and coding information can be found through Teva at the link below:
Cinqair patient assistance information can be found through Teva Support Solutions at the URL: https://www.tevasupportsolutions.com/patients/
CINQAIR prescribing information can be found at the link below:
Information regarding CINQAIR’s side effects can be found at MedlinePlus